Trial Profile
A Real-world study on treatment persistence with Golimumab in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) from French national health insurance database
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Nov 2016
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Therapeutic Use
- 12 Nov 2016 New trial record
- 02 Nov 2016 Results presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research